At this year’s ObesityWeek, GLP-1s aren’t the only talk of the townnews2024-11-06T14:23:27+00:00November 6th, 2024|Endpoints News|
New Trump era could be a boon for biopharma M&A, dealmakingnews2024-11-06T12:22:52+00:00November 6th, 2024|Endpoints News|
Novo unveils new cardiometabolic data as it reports solid third-quarter profitsnews2024-11-06T12:05:48+00:00November 6th, 2024|Endpoints News|
Acadia lands $150M sale of rare pediatric PRVnews2024-11-06T12:04:59+00:00November 6th, 2024|Endpoints News|
‘We’re good’ on weight loss: Biopharmas turn to muscle with new obesity drugsnews2024-11-06T12:00:14+00:00November 6th, 2024|Endpoints News|
One biotech is looking to lessen antipsychotic-induced weight gain, despite new entrantsnews2024-11-05T19:48:52+00:00November 5th, 2024|Endpoints News|
Cerebral to pay nearly $3.7M over controlled substance prescribing practicesnews2024-11-05T19:34:26+00:00November 5th, 2024|Endpoints News|
Catalent touts customer confidence ahead of Novo deal, but misses revenue estimatesnews2024-11-05T18:17:43+00:00November 5th, 2024|Endpoints News|
#ASH24: Novo Nordisk takes Forma’s sickle cell treatment into Phase 3news2024-11-05T17:55:25+00:00November 5th, 2024|Endpoints News|
Zealand details Phase 1 obesity data for amylin drug as it plans next stepsnews2024-11-05T17:15:38+00:00November 5th, 2024|Endpoints News|
